Maravai LifeSciences (NASDAQ:MRVI) Stock Price Up 4.3% on Insider Buying Activity

Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)’s stock price traded up 4.3% during mid-day trading on Tuesday after an insider bought additional shares in the company. The stock traded as high as $3.62 and last traded at $3.4850. 207,346 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 2,125,918 shares. The stock had previously closed at $3.34.

Specifically, CEO Bernd Brust purchased 216,212 shares of the business’s stock in a transaction on Thursday, November 13th. The stock was acquired at an average price of $3.25 per share, with a total value of $702,689.00. Following the purchase, the chief executive officer directly owned 466,771 shares in the company, valued at approximately $1,517,005.75. This represents a 86.29% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Bernd Brust acquired 93,358 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was purchased at an average price of $3.21 per share, with a total value of $299,679.18. Following the completion of the acquisition, the chief executive officer directly owned 250,559 shares in the company, valued at approximately $804,294.39. This represents a 59.39% increase in their position. The disclosure for this purchase is available in the SEC filing. In other Maravai LifeSciences news, CEO Bernd Brust bought 157,201 shares of Maravai LifeSciences stock in a transaction that occurred on Tuesday, November 11th. The shares were bought at an average price of $3.24 per share, with a total value of $509,331.24. Following the acquisition, the chief executive officer owned 157,201 shares in the company, valued at approximately $509,331.24. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the company. Royal Bank Of Canada reduced their price objective on Maravai LifeSciences from $7.00 to $5.00 and set an “outperform” rating for the company in a research report on Tuesday, August 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Maravai LifeSciences in a research note on Tuesday, October 14th. Three investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $5.22.

Maravai LifeSciences Stock Performance

The business has a 50-day moving average of $3.09 and a 200 day moving average of $2.62. The company has a debt-to-equity ratio of 0.74, a current ratio of 5.29 and a quick ratio of 4.56. The company has a market cap of $925.66 million, a PE ratio of -4.31 and a beta of 0.34.

Maravai LifeSciences (NASDAQ:MRVI) last released its quarterly earnings results on Thursday, November 6th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.02). Maravai LifeSciences had a negative net margin of 62.88% and a negative return on equity of 22.42%. The firm had revenue of $41.63 million for the quarter, compared to the consensus estimate of $49.02 million. Equities research analysts anticipate that Maravai LifeSciences Holdings, Inc. will post -0.24 EPS for the current fiscal year.

Institutional Trading of Maravai LifeSciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Callan Family Office LLC bought a new stake in shares of Maravai LifeSciences during the 2nd quarter valued at $25,000. Ethic Inc. bought a new position in Maravai LifeSciences in the 2nd quarter worth $26,000. Sprott Inc. purchased a new position in Maravai LifeSciences during the third quarter valued at $29,000. McAdam LLC bought a new stake in Maravai LifeSciences during the first quarter valued at about $31,000. Finally, Quantessence Capital LLC bought a new stake in Maravai LifeSciences during the third quarter valued at about $31,000. 50.25% of the stock is owned by hedge funds and other institutional investors.

About Maravai LifeSciences

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.